Results 1 to 10 of about 380,241 (292)

Programmed cell death protein 1 in cancer cells [PDF]

Cell Communication and Signaling
Programmed cell death protein 1 (PD-1) is frequently detected in certain subsets of tumor cells, and our understanding of PD-1 signaling consequences has expanded to include control of tumor growth, stemness and drug resistance.
Chunlian Wei, Meijun Liu, Weifen Zhang
doaj   +4 more sources

Are all programmed cell death protein 1 inhibitors the same? [PDF]

Frontiers in Oncology
Programmed cell death protein 1 (PD-1) inhibitors have revolutionized the treatment of many cancers, seven of which are approved by the US Food and Drug Administration (FDA).
Jochen H. Lorch, Stacey Stein, Martin J. Edelman   +2 more
doaj   +4 more sources

Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy

JTO Clinical and Research Reports, 2023
The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the model of antitumor therapy. With the continuous deepening of the research on the mechanism of immunotherapy, ICIs, such as programmed cell death protein 1 (PD-1), programmed ...
Yanyun Ao, BA, Ming Gao, MM, Binbin Sun, MD, Hongjun Hao, PhD, Huan Yan, MM, Chuntong Li, MD, Decong Sun, MD, Xuejiao Yang, BA, Yanfang Ju, MD, Xia Zhang, MD, Junxun Ma, MD   +10 more
doaj   +3 more sources

Hedgehog Pathway and Programmed Cell Death Protein-1 Inhibitors for Advanced Basal Cell Carcinoma [PDF]

Case Reports in Dermatology
Introduction: Basal cell carcinoma (BCC) is treated with local surgery or noninvasive treatment modalities. If a BCC remains untreated, it can develop into a locally advanced BCC or a metastatic BCC.
Babette J.A. Verkouteren, An K.L. Reyners, Maureen J.B. Aarts, Klara Mosterd   +3 more
doaj   +6 more sources

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

Chinese Medical Journal, 2020
. Historically, breast cancer has been regarded as an immunogenic “cold” tumor. However, the discovery of immune checkpoint inhibitors has made immunotherapy becoming an emerging new treatment modality for breast cancer.
Jing Zhao, Jian Huang, Qiang Shi
doaj   +3 more sources

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder [PDF]

Polish Journal of Pathology, 2021
Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1
Arbil Acikalin, Emine Bagir, Merve Inceman, Mutlu Deger, Seyda Erdogan   +4 more
doaj   +2 more sources

Acquired punctate palmoplantar keratoderma following Programmed cell death protein 1 inhibitor therapy [PDF]

JAAD Case Reports
Nandini Sarkar, BS, Janina Markidan, MD, Mark Gibbs, MD, Klaus Helm, MD   +3 more
doaj   +2 more sources

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment

Frontiers in Pharmacology, 2022
PD-1/PD-L1 play key roles in tumor immune escape and the formation of the tumor microenvironment, and are closely related to the generation and development of tumors.
Feng Li, Feng Li, Binchi Liao, Ting Wang, Tingting Qi, Yixin Wang   +5 more
doaj   +1 more source

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib

Technology in Cancer Research & Treatment, 2023
Background: Programmed cell death protein-1 inhibitors combined with lenvatinib have become a popular treatment option for patients with unresectable hepatocellular carcinoma.
Jinfeng Wang MM, Man Zhao MM, Guangjie Han MM, Xin Han MM, Jianfei Shi PhD, Lili Mi PhD, Ning Li BM, Xiaolei Yin MM, Xiaoling Duan PhD, Jiaojiao Hou MM, Fei Yin PhD   +10 more
doaj   +1 more source

D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER

Pakistan Armed Forces Medical Journal, 2021
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer cases and its correlation with clinicopathological factors. Study Design: Cross sectional study. Place and Duration of Study: Histopathology department,
Sammeen Salim, Muhammad Asif, Rabia Ahmed, Muhammad Tahir Khadim   +3 more
doaj   +1 more source